Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Acta Neurol Scand Suppl
; 95: 123-6, 1983.
Article
in En
| MEDLINE
| ID: mdl-6428144
ABSTRACT
Long-term treatment of parkinsonian patients with levodopa (plus decarboxylase inhibitor) leads to decreasing levodopa efficacy and increasing side-effects. Then main therapeutic problems are on-off phenomena, end-of-dose akinesia and levodopa-induced dyskinesias. Deprenyl, a selective MAO-B inhibitor, has produced good therapeutic effects in combination either with levodopa alone or with levodopa plus decarboxylase inhibitor in the treatment of end-of-dose akinesia and on-off phenomena. In an open trial with 48 parkinsonian patients deprenyl was added to previous levodopa plus decarboxylase-inhibitor therapy. Good effects were achieved in respect of mild on-off phenomena and end-of-dose akinesia, minor success in the alleviation of dyskinesia and depression. In four further patients with a post-traumatic parkinsonian syndrome, no improvement of rigidospasticity and vigilance was demonstrable.
Search on Google
Database:
MEDLINE
Main subject:
Parkinson Disease
/
Phenethylamines
/
Selegiline
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Acta Neurol Scand Suppl
Year:
1983
Type:
Article